ReviewBiotechnology and bioengineering2021
The transition of Rhodobacter sphaeroides into a microbial cell factory.
Review in Biotechnology and bioengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A non-classical biosynthetic route enables tocopherol synthesis in bacteria.Nature metabolism · 2026Article
- Heterologous expression of lipase gene in Cereibacter sphaeroides 2.4.1 driven by an anaerobic Photosynthesis-Inducible promoter.Journal, genetic engineering & biotechnology · 2026Article
- A Sequence-Based Approach Reveals a Novel Family IV Lipolytic Enzyme in Cereibacter sphaeroides 2.4.1.Molecular biotechnology · 2026Article
- Rhodo-Box: A Synthetic Biology Toolbox to Facilitate Metabolic Engineering ofACS synthetic biology · 2026Article
- Extracellular Metabolite Profiling in COMetabolites · 2026Article
- Gas-Phase Integration of Trophically Distinct Microbial Cultures for Net-Reduced COMicrobial biotechnology · 2025Article
- High-yield porphyrin production through metabolic engineering and biocatalysis.Nature biotechnology · 2025Article
- Systematic engineering to enhance valencene production in Rhodobacter sphaeroides.Bioresources and bioprocessing · 2025Article
- Myxobacteria: Versatile cell factories of novel commercial enzymes for bio-manufacturing.Biotechnology advances · 2025Review
- Insights into genetic determinants of volatile fatty acid catabolism inApplied and environmental microbiology · 2025Article
- Quantitative Analysis ofBiomolecules · 2024Article
- Impacts of Groundwater Pumping on Subterranean Microbial Communities in a Deep Aquifer Associated with an Accretionary Prism.Microorganisms · 2024Article
- Pseudomonas putida as a platform for medium-chain length α,ω-diol production: Opportunities and challenges.Microbial biotechnology · 2024Article
- Synergistic investigation of natural and synthetic C1-trophic microorganisms to foster a circular carbon economy.Nature communications · 2023Review
- Review
- Microbiome diversity, composition and assembly in a California citrus orchard.Frontiers in microbiology · 2023Article
- Regulation of Reactive Oxygen Species Promotes Growth and Carotenoid Production Under Autotrophic Conditions inFrontiers in microbiology · 2022Article
- Screening and engineering of high-activity promoter elements through transcriptomics and red fluorescent protein visualization inSynthetic and systems biotechnology · 2021Article
- The transition of Rhodobacter sphaeroides into a microbial cell factory.Biotechnology and bioengineering · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Microbial cell factories are the workhorses of industrial biotechnology and improving their performances can significantly optimize industrial bioprocesses. Microbial strain engineering is often employed for increasing the competitiveness of bio-based product synthesis over more classical petroleum-based synthesis. Recently, efforts for strain optimization have been standardized within the iterative concept of "design-build-test-learn" (DBTL). This approach has been successfully employed for the improvement of traditional cell factories like Escherichia coli and Saccharomyces cerevisiae. Within the past decade, several new-to-industry microorganisms have been investigated as novel cell factories, including the versatile α-proteobacterium Rhodobacter sphaeroides. Despite its history as a laboratory strain for fundamental studies, there is a growing interest in this bacterium for its ability to synthesize relevant compounds for the bioeconomy, such as isoprenoids, poly-β-hydroxybutyrate, and hydrogen. In this study, we reflect on the reasons for establishing R. sphaeroides as a cell factory from the perspective of the DBTL concept. Moreover, we discuss current and future opportunities for extending the use of this microorganism for the bio-based economy. We believe that applying the DBTL pipeline for R. sphaeroides will further strengthen its relevance as a microbial cell factory. Moreover, the proposed use of strain engineering via the DBTL approach may be extended to other microorganisms that have not been critically investigated yet for industrial applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.